Bone Biologics Appoints New Chief Executive Officer And A Chief Operating Officer
EDISON, N.J., Aug. 13, 2015 /PRNewswire/ -- Bone Biologics Corporation, (“Bone Biologics” or “The Company”) announced today the appointment of Mr. Stephen R. La Neve as the Company’s Chief Executive Officer and President, and Mr. Jeffrey Frelick as the Company’s Chief Operating Officer, each to be effective on August 17, 2015. Mr. La Neve replaces our interim Chief Executive Officer, Michael Schuler.
Steve La Neve brings thirty years of health care experience, leadership and success to Bone Biologics. Prior to his new position, Steve held leadership roles in the device and diagnostic segments which include: CEO and president of Etex Corporation; president of Becton Dickinson’s Pre-Analytical Systems business; president of Medtronic’s $3.5b Spine and Biologics business; and president of Medtronic’s second largest country business unit, Medtronic Japan. He also served as senior vice president and executive vice president at Premier, one of the largest GPOs in the United States and ran the global Injection Systems business unit for Becton Dickinson. He serves on the board of directors for SkelRegen, LLC and Rapid Pathogen Screening, Inc. (RPS), and he consults for private equity companies in the medical device area. Steve holds a B.S. in Health Planning and Administration from Pennsylvania State University, an M.B.A. from West Chester University, and is a member of the Omicron Delta Epsilon honor society for academic excellence in economics.
Jeff Frelick was most recently the COO of Life Science Enterprises, and brings more than 25 years of med-tech experience to BBC. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Jeff worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Jeff received a B.S. in Biology from University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School.
Bone Biologics Board Chairman Bruce Stroever stated, “We are very pleased to have individuals of the caliber of Steve and Jeff join our company. We have a very exciting technology and now have the full time management to bring this product to market. We’re also thankful for the time Mike Schuler dedicated to BBC in his role as interim CEO as he returns to his position with MTF.” Mr. Stroever is the President and CEO of MTF.
visit: www.bonebiologics.com
About Bone Biologics
Bone Biologics was founded by University of California Los Angeles professors in collaboration with an Osaka University professor, and a USC surgeon in 2004. Formed to pursue regenerative medicine for bone, the company currently has as its strategic partners the Musculoskeletal Transplant Foundation, the nation’s leading tissue bank and Orthofix a leading global medical device company. Bone Biologics is currently focused on bone regeneration in spinal fusion using its recombinant human protein known as Nell-1. Nell-1 is an osteoinductive orthobiologic; a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA.
About MTF
The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987 MTF has received tissue from more than 100,000 donors and distributed more than five million grafts for transplantation. For more information
visit: www.mtf.org
Forward-Looking Statements
This press release contains forward-looking statements that reflect the Company’s current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “will,” “will be,” “anticipate,” “predict,” “continue,” “future,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent current report on Form S-1/A, filed with the Securities and Exchange Commission on April 30, 2015. The Company anticipates that subsequent events and developments may cause their views and expectations to change. The Company assumes no obligation, and they specifically disclaim any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
For Information contact:
William Jay Treat, Ph.D., (732-661-2224)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bone-biologics-corporation-appoints-new-chief-executive-officer-and-a-chief-operating-officer-300128331.html
SOURCE Bone Biologics Corporation
Help employers find you! Check out all the jobs and post your resume.
